These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14561538)

  • 1. Effect of a low-dose oral contraceptive containing 20 microg ethinylestradiol and 150 microg desogestrel on dysmenorrhea.
    Callejo J; Díaz J; Ruiz A; García RM
    Contraception; 2003 Sep; 68(3):183-8. PubMed ID: 14561538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
    Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol.
    Winkler UH; Ferguson H; Mulders JA
    Contraception; 2004 Jun; 69(6):469-76. PubMed ID: 15157791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
    Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML; Schmidt J
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive.
    Hendrix SL; Alexander NJ
    Contraception; 2002 Dec; 66(6):393-9. PubMed ID: 12499030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
    Gaspard U; Scheen A; Endrikat J; Buicu C; Lefebvre P; Gerlinger C; Heithecker R
    Contraception; 2003 Jun; 67(6):423-9. PubMed ID: 12814810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
    Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
    Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial.
    Harada T; Momoeda M; Taketani Y; Hoshiai H; Terakawa N
    Fertil Steril; 2008 Nov; 90(5):1583-8. PubMed ID: 18164001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a phasic oral contraceptive containing desogestrel on facial seborrhea and acne.
    Prilepskaya VN; Serov VN; Zharov EV; Golousenko IJ; Mejevitinova EA; Gogaeva EV; Yaglov VV; Golubeva ON
    Contraception; 2003 Oct; 68(4):239-45. PubMed ID: 14572886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen.
    Vercellini P; Frontino G; De Giorgi O; Pietropaolo G; Pasin R; Crosignani PG
    Fertil Steril; 2003 Sep; 80(3):560-3. PubMed ID: 12969698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.
    Vercellini P; Trespidi L; Colombo A; Vendola N; Marchini M; Crosignani PG
    Fertil Steril; 1993 Jul; 60(1):75-9. PubMed ID: 8513962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance.
    Endrikat J; Jaques MA; Mayerhofer M; Pelissier C; Müller U; Düsterberg B
    Contraception; 1995 Oct; 52(4):229-35. PubMed ID: 8605781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latin american experience with two low-dose oral contraceptives containing 30 microg ethinylestradiol/75 microg gestodene and 20 microg ethinylestradiol/150 microg desogestrel.
    Bassol S; Alvarado A; Celis C; Cravioto MC; Peralta O; Montaño R; Novelli J; Albornoz H; Kesseru E; Soares A; Petracco A; Isaia B; Mendes J; Bahamondes L; de Melo NR; Reyes-Marquez R; Albrecht G
    Contraception; 2000 Sep; 62(3):131-5. PubMed ID: 11124360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
    Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
    Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
    Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
    Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.